Clin2
NCT06937307Worth exploringRecruiting

Droxidopa for low blood pressure in cirrhosis with kidney injury

Acute Kidney InjuryCirrhosisDecompensated Cirrhosis of Liver

Treatments studied

Part of Kidney & urinary, Women’s health & pregnancy clinical trials.

This trial tests a medication called droxidopa to see if it can raise blood pressure in people with cirrhosis who also have acute kidney injury. If you have low blood pressure and are in the hospital with these conditions, this study may help improve your kidney function.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
75 people
Ages
18 years to 70 years
Study type
Interventional

Who can take part

  • You are 18 to 70 years old and currently in the hospital at Columbia University Irving Medical Center.
  • You have cirrhosis (liver scarring) that is at least moderate (Child-Pugh B or higher) and you have acute kidney injury (a sudden drop in kidney function).
  • Your average blood pressure over the last 24 hours is 85 mmHg or lower.
  • You can take medications by mouth and agree to blood and urine tests.
  • You do not have severe heart disease, active internal bleeding, severe breathing problems, or certain medical conditions that could interact with the study drug.
  • You have not had a liver transplant and are not pregnant or breastfeeding.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06809088Not yet recruiting
Comparing two ways of giving albumin for kidney injury in cirrhosis

This trial tests whether giving albumin (a blood protein) in a personalized dose works better than a standard fixed dose for people with cirrhosis and sepsis-related acute kidney injury. The goal is to find a safer and more effective way to protect kidney function.

New Delhi, National Capital Territory of Delhi
NCT03629418Recruiting
Blood-pressure strategy to prevent kidney injury after heart bypass

This trial tests a targeted way to manage blood pressure before and after off-pump heart bypass surgery, with the goal of reducing acute kidney injury (sudden kidney problems). It may help some people by lowering stress on the kidneys during and right after surgery.

Beijing, Beijing Municipality
NCT01370512Enrolling by invitation· Phase 2
Droxidopa plus pyridostigmine for low blood pressure on standing

This Phase 2 study tests whether the medicines droxidopa and pyridostigmine can improve symptoms of orthostatic hypotension, which is low blood pressure when you stand up. It is designed for people whose low blood pressure is caused by problems with the nerves that control blood pressure.

Rochester, Minnesota
NCT02897063Recruiting· Phase 1
Test medicines for low blood pressure in nerve-related disorders

This early (Phase 1) study tests whether midodrine and droxidopa can improve blood-flow pooling in the belly in people with nerve problems that affect blood pressure when standing. It’s looking at safety and how the body responds, which may help reduce dizziness or fainting for some participants.

Nashville, Tennessee
NCT06695611Not yet recruiting
Blood pressure targets study for dialysis patients

This trial tests different blood pressure goals for people receiving dialysis at a center. It aims to find which target is safest and most effective for managing blood pressure during treatment.

Winnipeg, Manitoba
NCT05732727Recruiting· Phase 3
Stronger BP lowering using diuretics in kidney disease

This Phase 3 trial compares a plan that uses diuretics (water pills) to lower blood pressure more, versus usual blood pressure care, in people with uncontrolled hypertension and moderate-to-severe chronic kidney disease. It may help your blood pressure control while monitoring safety closely because kidney function changes how medicines work.

Angers

Hear when a new Acute Kidney Injury trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.